| A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer (NCT05431569) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-07-10 |
| The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer. (NCT05279521) | National Taiwan University Hospital | 2022-03-20 |
| IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 (NCT05805956) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-02-15 |
| Study of JS004 Combined With Toripalimab for Advanced Lung Cancer (NCT05000684) | Shanghai Junshi Bioscience Co., Ltd. | 2021-08-27 |
| A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC (NCT04672369) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-06-06 |
| A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer (NCT04672356) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-01-25 |
| Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer (NCT04670445) | Massachusetts General Hospital | 2021-01-23 |
| A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer (NCT06183762) | Hunan Province Tumor Hospital | 2020-01-01 |
| Descriptors and Predictors of Burden and Information Needs (NCT04069494) | Chulabhorn Cancer Center | 2019-10-01 |
| Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL) (NCT04575831) | University of Calgary | 2019-09-01 |
| Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer (NCT03751592) | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | 2018-07-17 |
| MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) (NCT03004105) | M.D. Anderson Cancer Center | 2018-05-01 |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer (NCT03501056) | Fuda Cancer Hospital, Guangzhou | 2018-03-27 |
| CAR-T Cell Immunotherapy for Advanced Lung Cancer (NCT03330834) | Sun Yat-sen University | 2017-11-20 |
| Enhancing Quality of Life in Patients (EQUIP) Intervention for Patients With Advanced Lung Cancer (NCT02801734) | National Cancer Centre, Singapore | 2016-08-01 |
| Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer (NCT02873416) | Ningbo Cancer Hospital | 2016-08-01 |
| Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer (NCT02862587) | Shanghai International Medical Center | 2016-08-01 |
| Cambridge Brain Mets Trial 1 (NCT02768337) | Cambridge University Hospitals NHS Foundation Trust | 2015-03-10 |
| A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations (NCT02109016) | Clovis Oncology, Inc. | 2014-04-01 |
| Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers (NCT01579994) | Memorial Sloan Kettering Cancer Center | 2012-04-16 |